Get Bars 7-OH Tablets Reviews 2026: What’s in the Pack? Inside the Product Lines, Labels, and Lab Reports
A closer look at Get Bars’ 7-OH and 7OH-Alternative tablets, brand-stated ingredients, published batch reports, pricing, and the questions the available information leaves unanswered.
Advertorial notice: This is advertorial content, promotional in nature and intended for consumer education about a commercially available product. It contains no affiliate links, isn’t medical advice, and doesn’t recommend buying or using anything. Brand statements are the brand’s own and haven’t been independently verified. Brand website: getbars.co. Reviewed October 3, 2026.
Get Bars 7-OH Tablets Reviews: Researching Lab Reports, FDA Position and DEA Status Explained (Consumer Research)
TL;DR: Get Bars 7-OH Tablets are flavored kratom-alkaloid tablets sold at getbars.co in two separate lines: 7-OH tablets labeled 30mg or 60mg per tablet, and a “7OH-Alternative” line the brand says contains no 7-OH. As reviewed October 3, 2026, the FDA classifies 7-OH as a potent opioid. The DEA has filed a notice of intent, rather than an effective order, to schedule 7-OH above a specific threshold. Three related compounds were placed in Schedule I on August 26, 2026.
Last verified: October 3, 2026. Prices, strengths, shipping lists, and legal status are all dated because each can change rapidly. Federal status for 7-OH is re-checked before publication and updated whenever the DEA acts on Docket DEA-1570.
If you encountered Get Bars in an advertisement, a social feed, or a search result and want the full picture first, this page is designed for you. In about five minutes, you will understand what the product is, what its lab reports indicate, what the FDA and DEA have officially documented, and which questions remain unanswered.
Get Bars 7-OH Tablets: Quick Verification Snapshot (As Reviewed October 3, 2026)
What Are Get Bars 7-OH Tablets?
Get Bars 7-OH vs. Get Bars 7OH-Alternative: Two Different Product Families
What Product Strengths Does Get Bars Currently List?
What Do the Get Bars Lab Reports Show?
How to Read a Certificate of Analysis (COA)
What Is 7-Hydroxymitragynine (7-OH)?
Concentrated 7-OH vs. Natural Kratom Leaf: What’s the Difference?
What Has FDA Said About 7-OH?
What Is the Current DEA Status of 7-OH?
Notice of Intent vs. Temporary Scheduling Order: A Plain-English Timeline
How Do the Proposed Thresholds Compare With the Brand’s Reported Numbers?
Which State Restrictions Apply?
Get Bars Pricing and Shipping Information (As Reviewed October 3, 2026)
What Does the Get Bars Refund Policy Say?
What the Brand’s Reviews and Marketing Language Include
Known Safety, Dependence, and Interaction Concerns From Authoritative Sources
What Information Remains Unverified
How to Check Current Status Yourself
Get Bars 7-OH Tablets Fast Facts
Quick Answers About Get Bars 7-OH Tablets
The Bottom Line on Get Bars 7-OH Tablets
Official brand website: getbars.co. The brand’s Terms identify BARS as associated with 113 Ventures, LLC.
Two product families: conventional “BARS 7 Hydroxy Tablets” and a separate “7OH-Alternative” line the brand says is built on a proprietary blend called Mitraxidine.
7-OH strengths: the brand’s pages are inconsistent. Product listings show 60mg for several flavors, while a collection page claims the “primary formula” delivers 30mg and its table lists some flavors at 30mg.
Alternative tablets: the product page describes 4 tablets per pack, 16 servings per pack, 300mg of Mitraxidine per tablet, and 75mg per quarter-tablet serving.
Brand-posted lab report, 60mg Watermelon (Batch 14-31-058): 7-OH at 60.5 mg per serving, 242 mg per package, and 21.6 percent by weight.
Brand-posted lab report, 7OH-Alternative Mixed Berry (Batch MB082526): 7-OH not detected; mitragynine at 7.454 percent.
FDA: describes 7-OH as a potent opioid and states it isn’t lawful in dietary supplements or conventional foods. No FDA-approved drug contains it.
DEA, 7-OH (Docket DEA-1570): notice of intent published July 6, 2026. No later temporary scheduling order was located.
DEA, related compounds (Docket DEA-1644): mitragynine pseudoindoxyl, MGM-15, and MGM-16 were temporarily placed in Schedule I, effective August 26, 2026.
Return terms: the brand’s site shows both a 60-day and a 30-day window.
Brand contact: Info@GetBars.co.
State law: restrictions vary by state and by product; the brand’s shipping restrictions differ from page to page.
Short answer: According to the brand’s website, Get Bars sells flavored chewable tablets under the BARS name. Here is what the brand’s own pages state:
Format: multi-tablet packs, with each tablet described as breaking into four servings.
Age: packaging shows “21+ Only,” and the site opens with an age-confirmation prompt.
Quality claims: the brand calls the tablets lab-tested and says they are produced in a Current Good Manufacturing Practices (cGMP) facility. The materials reviewed do not identify the manufacturer, so the cGMP statement is the brand’s claim and was not verified here.
Marketing: the brand markets the tablets for psychoactive consumer experiences. That is not validated here and should not be interpreted as an established health or therapeutic effect. Product pages carry a “may cause psychotropic effects” warning and advise consulting a physician.
Labeling: the Mixed Berry 7OH-Alternative page, the Winter Mint page, and the 7-OH collection page show no Supplement Facts panel or standard dietary-supplement disclaimer regarding FDA evaluation. They use an “Ingredients” section instead.
Short answer: Get Bars operates two separate product lines, and search results often conflate them.
BARS 7 Hydroxy Tablets: described by the brand as containing 7-hydroxymitragynine. The brand-posted Watermelon 60mg report lists 7-OH as the principal measured alkaloid at a concentrated level.
BARS 7OH-Alternative Tablets: built, per the brand, on a proprietary kratom-derived blend called Mitraxidine. On the Mixed Berry page, the brand states the product contains no 7-OH, mitragynine pseudoindoxyl, MGM-15, or MGM-16, and the same page uses the phrases “legal alternative” and “fully legal.”
What this article adopts: none of the brand’s lawfulness language. It does not independently conclude that any product is lawful anywhere, and it does not define what Mitraxidine is chemically, because the reviewed materials call it only a proprietary blend.
What the record shows: one brand-posted report for one flavor (Mixed Berry, Batch MB082526) that lists 7-OH as not detected. One batch does not establish what other flavors or batches contain.
Brand blog excerpt: an excerpt seen in search results (not opened in full) describes the Mitraxidine tablets as formulated to be as close as possible to a one-to-one substitute for the earlier 7-hydroxy tablets. That is marketing language, and it is one reason the distinction between the two families matters.
As reviewed October 3, 2026, the brand’s pages provide these figures. Everything below is brand-stated labeling information, not a use recommendation.
60mg 7-OH line: product listings show “60mg” with “240mg total” per four-tablet pack for Watermelon, Blue Raspberry, and Mixed Berry.
30mg 7-OH line: the Winter Mint page reads “30mg 7-Hydroxy per tablet,” with four servings per tablet and 16 servings per container, and the packaging images show 30MG per tablet and 120MG per package.
7OH-Alternative line: 300mg of Mitraxidine per tablet, four tablets per pack, 16 servings per pack, and 75mg per quarter-tablet serving.
The alternative line’s numbers add up on their face.
The product page states four 300mg tablets per pack, each tablet split into four servings. That results in 1,200mg per pack and 75mg per serving, and the figures are internally consistent.
Where the brand’s strength information still conflicts.
The 7-OH collection page says the primary formula delivers 30mg of 7-hydroxymitragynine in every four-serving tablet. The table on the same page lists Blue Raspberry, Mixed Berry, and Watermelon at 60mg, and Winter Mint and White Grape at 30mg.
The brand’s current pages contain conflicting strength references for White Grape: the package text shown on the storefront lists 60MG per tablet, while the collection page table lists 30mg.
The Mixed Berry 7OH-Alternative lab report lists a package weight of 1.032 grams (1,032 mg) and a serving weight of 0.065 grams (65 mg). The product page lists 1,200mg of Mitraxidine per pack and 75mg per serving. The materials do not explain how those figures relate, for example whether the lab weights reflect the whole tablet, the sampled units, or something else. The label’s 1,200mg figure should not be interpreted as 1,200mg of any measured alkaloid.
These reviewed materials do not resolve these discrepancies, and anyone comparing products would need the brand to clarify what each figure measures.
Short answer: Two brand-posted certificates of analysis were reviewed. They were not commissioned or authenticated by this article, text extraction from the PDFs was partial in places, and a potency report does not establish safety, effectiveness, or legality. The downloads are on the brand’s Lab Reports page.
Watermelon 60mg, Batch 14-31-058
Report: potency certificate produced June 30, 2026, by Infinite Chemical Analysis Labs (San Diego, California).
Sample listed as: “BARS x TRE House 7-OHM Kratom Tablets – Watermelon 60mg – 4ct (Concentrate).”
7-OH: 60.5 mg per serving, 242 mg per package, 21.6 percent by weight.
Weights: 0.28 g serving; 1.12 g package.
Other results: mitragynine below the limit of quantitation; mitragynine pseudoindoxyl and MGM-15 not detected.
Report note: no compliance regulations were applied to the potency test.
Second certificate, same batch number: produced June 16, 2026, covering solvents, metals, microbial, mycotoxin, and pesticide panels, with an overall pass against the limits shown.
Details listed: client CBDfx; matrix “Edible Solid”; 1.05 g package; 0.26 g serving.
Open question: the two records for one batch differ on client name, matrix, and weights, and the reviewed materials do not explain why.
7OH-Alternative Mixed Berry, Batch MB082526
Report: certificate produced September 8, 2026, by SC Labs (Warren, Michigan).
Sample listed as: “BARS X TRE House 7-OH Alternative Tablets – Mixed Berry 1200mg – 4ct.”
Weights: 0.065 g serving; 1.032 g package.
7-OH: not detected.
Mitragynine: 7.454 percent (4.845 mg per serving; 76.925 mg per package). Paynantheine: 0.308 percent.
Related compounds: mitragynine pseudoindoxyl and MGM-15 appear as not detected as extracted; the MGM-16 row did not extract cleanly.
Report notes: “for quality assurance purposes only,” with its synthetic alkaloid and kratom potency sections marked beyond the lab’s accreditation scope.
What the lab report index does not show.
It lists no report for the Orange Citrus 7OH-Alternative product that appears on the storefront.
It lists no reports for the 30mg products on the page reviewed.
Only two reports were opened. Nothing here describes other flavors, strengths, or batches.
Lab reports can look intimidating, and a few details make them much easier to read. These are general reading tips, not a judgment about any particular document.
Match the batch: the batch number on the report should match the batch of the product you are comparing it with.
Check who ran the test: look for the laboratory’s name and accreditation, and note any sections marked as beyond the lab’s accredited scope.
Read the units: results can be shown as milligrams per serving, milligrams per package, or percent by weight, and the serving size defined on the report may differ from the serving size on a label.
Know the shorthand: “ND” means not detected, and “LOQ” is the limit of quantitation, the lowest amount the lab can reliably measure.
Look at the date and the client: reports can be old, and the client named on the report may differ from the brand selling the product.
Remember what a COA cannot show: a potency report describes the sample tested. It does not establish safety, effectiveness, or legality.
Short answer: 7-hydroxymitragynine (7-OH) is a minor alkaloid associated with the kratom plant (Mitragyna speciosa), a tropical tree native to Southeast Asia.
Natural levels: according to the FDA’s scientific assessment, it makes up less than 2 percent of total alkaloid content in leaf, and typically no more than roughly 0.01 to 0.04 percent by dry weight.
Pharmacology: the FDA describes 7-OH as a mu-opioid receptor agonist, the receptor family targeted by morphine and fentanyl, and reports greater potency than morphine in preclinical studies.
Evidence limits: the FDA knew of no clinical studies using isolated, purified 7-OH, so much of the evidence comes from laboratory and animal work.
DEA: its notices describe similar opioid-type activity.
Botanical kratom leaf: contains 7-OH only in trace amounts. The threshold in the DEA’s notice separates material above a specified 7-OH level from material at or below it, and the FDA has separately distinguished concentrated 7-OH products from the much lower levels found naturally in leaf, while continuing to raise broader safety concerns about kratom products.
Concentrated or “enhanced” 7-OH products: contain far more 7-OH than the plant holds. The FDA’s assessment says the extra 7-OH is likely produced by chemically converting mitragynine, because extracting large quantities directly from leaf would be impractical. The DEA’s notice says the lab-made and naturally occurring molecule are structurally identical.
A word like “botanical” on a label describes an origin story, not a concentration. In the one 60mg lab report reviewed, 7-OH was reported at 21.6 percent by weight, which is hundreds of times the plant’s trace range.
The FDA’s position, as published in its materials, comes down to these points:
The FDA describes 7-OH as a potent opioid that poses an emerging public health threat, especially in concentrated products.
The FDA’s assessment states that kratom, mitragynine, and 7-OH are not lawful when added to conventional foods, sold as dietary supplements, or used in any FDA-approved drug, and that no FDA-approved drug contains kratom or 7-OH for any therapeutic indication.
The DEA’s notice reports that the FDA sent seven warning letters in June and July 2025 to marketers of 7-OH products.
In July 2025, the FDA recommended that concentrated 7-OH be placed in Schedule I. HHS later told the DEA, in a March 6, 2026 letter, that it had no objection to the temporary placement the DEA proposed.
The FDA’s 7-OH page, with content current as of July 13, 2026, links to a consumer guide, a letter to health care professionals, and announcements about warning letters and seizures.
These are the FDA’s statements about 7-OH products generally. This article does not claim the FDA has made a finding about Get Bars specifically.
The reviewed Get Bars pages show no FDA approval, and this article does not classify the product as a dietary supplement.
Primary
The DEA announced two actions on July 1, 2026, and the Federal Register published both on July 6, 2026. They moved on different tracks, so each gets its own answer.
7-OH above a specified threshold (Docket DEA-1570): notice of intent only.
What it says: the DEA intends to issue a temporary scheduling order placing 7-OH above a specified threshold in Schedule I (notice of intent, 91 FR 40917).
Threshold: more than 0.050 percent 7-OH by dry weight for kratom plant material. For other articles such as extracts, concentrates, edibles, or pressed pills: more than 0.050 percent by weight or volume, or more than 1.00 milligram of 7-OH in the article.
Timing: not before August 5, 2026; effective the day it is published in the Federal Register; two years, with a possible one-year extension.
Status as of October 3, 2026: no temporary scheduling order for 7-OH under DEA-1570 was located. On a same-day re-check, the Federal Register page for the notice pointed to no later order (the companion notice for the related compounds does point to its order), and a news roundup dated October 1, 2026, describes the 7-OH scheduling as still pending.
HHS: opened a request for information on the proposed threshold and, by a notice published August 26, 2026, extended its comment period to September 10, 2026.
What this means: a notice of intent is not the temporary scheduling order. This article therefore does not state that the DEA has banned 7-OH, and it does not state that 7-OH is federally Schedule I.
Three related compounds (Docket DEA-1644): order in effect.
Order: DEA temporary scheduling order, 91 FR 54948, published August 26, 2026 (Docket DEA-1644).
Substances: mitragynine pseudoindoxyl, MGM-15, and MGM-16.
Dates: effective August 26, 2026, through August 26, 2028, unless extended or made permanent.
Retail sales: the order states that retail sales of Schedule I substances to the general public are not allowed under the Controlled Substances Act.
Why one brand-page detail matters here.
7OH-Alternative page: states the product contains none of these compounds.
Collection page table: shows “No” under “Contains Pseudo” for the five 7-OH flavors.
Winter Mint page (marked noindex): still carries language offering “Orange Citrus 7OH + Pseudo Tablets” and an ingredient line reading “7-Hydroxymitragynine 30mg or 7-Hydroxymitragynine + Pseudo.”
Why it is flagged: mitragynine pseudoindoxyl became Schedule I on August 26. This article does not determine whether any currently sold product contains it, and the page text may be outdated. The brand would need to clarify which pages are current.
July 28 to 29, 2025: HHS sends the DEA a scientific evaluation, and the FDA publicly recommends Schedule I placement for concentrated 7-OH.
December 15, 2025 and February 24, 2026: the DEA notifies HHS of its intent for the related compounds and for 7-OH, respectively; HHS replies it has no objection (January 20 and March 6, 2026).
July 1, 2026: the DEA announces two notices of intent.
July 6, 2026: both notices and the HHS request for information are published.
August 5, 2026: earliest date a temporary order could issue.
August 26, 2026: the related-compounds order takes effect; HHS extends the comment period.
September 10, 2026: the extended HHS comment period closes.
Not located as of October 3, 2026: a temporary scheduling order for 7-OH under DEA-1570.
This is arithmetic, not a legal determination. Whether a specific product is covered depends on the final order’s text, the product’s composition, and how it is applied.
For numerical context only, the reviewed Watermelon report lists 7-OH at 21.6 percent by weight. Mathematically, that concentration is approximately 432 times the 0.050 percent figure that appears in the DEA’s notice. This comparison does not determine how the DEA would classify or treat a particular product.
The same report lists 60.5 mg of 7-OH per laboratory-reported serving.
The 7OH-Alternative Mixed Berry report shows 7-OH as not detected, so that comparison would not apply to that sample on the data in hand.
The threshold itself is debated. One policy-group comment in the HHS docket argues the evidence supports concern about 7-OH’s opioid hazards but does not identify 1.00 mg or 0.050 percent as the point where an imminent hazard begins. That is a stated view in a public comment, not an agency finding.
State law is the least settled part of this topic, and a seller’s shipping list is not legal authority.
The brand’s shipping restrictions differ by page.
Shipping information page: its 7OH tablets are restricted in Alabama, Arkansas, California, Georgia, Indiana, Louisiana, Rhode Island, Texas, Utah, Vermont, and Wisconsin (brand page).
Mixed Berry 7OH-Alternative page: a different “does not ship to” list covering Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Massachusetts, Tennessee, and Wisconsin.
Takeaway: no single list applies to every Get Bars product.
What the DEA’s notice says about states.
The DEA’s notice: citings, Florida, Indiana, Kentucky, Louisiana, Ohio, Vermont, and Wisconsin) as prohibiting 7-OH consumption
Other approaches: several states cap 7-OH as a share of alkaloid content, and 19 states have adopted a Kratom Consumer Protection Act framework.
Preemption: the DEA’s action does not override more restrictive state law.
Tennessee: Matthew Davenport’s Law (Public Chapter 950) took effect July 1, 2026. Tennessee’s Department of Mental Health and Substance Abuse Services states that possession, manufacture, or sale of kratom is banned statewide and that the law expanded the state’s prior restrictions to cover the plant and manufactured kratom products.
Ohio: Ohio Administrative Code rule 4729:9-1-01.1, effective May 19, 2026, classifies mitragynine-related compounds, including 7-hydroxymitragynine, mitragynine pseudoindoxyl, dihydro-7-hydroxymitragynine, and 7-acetoxymitragynine, as Schedule I controlled substances under state law. The rule excludes mitragynine in natural leaf vegetation form (Ohio rule text).
Other states: Tennessee and Ohio were verified against official statecle does not state a current Florida position, and other states were not individually verified against primary authority
Check your state’s legislature, health department, or board of pharmacy before relying on anything here for a specific location.
These terms are reported as the brand states them and are not an invitation to purchase.
Listed prices: the storefront shows $34.99 as the current price against a crossed-out $49.99 on the individual flavors reviewed, with a Variety Pack at $24.99 against $35.99. The crossed-out figures are brand-displayed reference prices, not independently verified prior prices.
The “40% off” language: a banner reads “Subscribe & Save 40% Off + Free Shipping,” a button reads “Get 40% Off,” and an email form reads “40% off your first order.” The Terms and Refund pages reviewed contain no subscription terms, cancellation method, or billing cycle, so how the offer works remains unconfirmed.
Free shipping: the Terms describe a free USPS option taking 5 to 8 business days; processing can take up to 72 hours; delivery estimates are not guaranteed; and shipping charges are non-refundable. The product pages reviewed add that free shipping applies to orders of $75 or more after discounts, so it does not apply automatically to every order.
Age: the site requires 21 or older, while the privacy policy’s mailing-list section refers to consumers 18 or older.
Dispute terms: the Terms name 113 Ventures, LLC; California law; binding JAMS arbitration; and a class-action waiver with a small-claims exception.
Privacy: the privacy policy says information may be shared among affiliated companies and lists categories that can include driver’s license numbers and parts of Social Security numbers. Read it in full before sharing personal information with any site.
The brand’s legal pages contain two return windows, and the reviewed text does not say which one governs.
Terms and Conditions: 60 days from the order date for unopened, unused items in original packaging, with an RMA request by email, customer-paid return shipping on non-defective returns, a 25 percent restocking fee for defective items showing physical damage, and refunds within 3 to 5 business days of receipt.
Refund and Return Policy page: a “30-Day Guarantee” from the order date for unopened products or items containing a reasonable amount of unused product, with only unopened or minimally used items qualifying.
This article cannot determine which version controls. Confirm current terms with the brand at Info@GetBars.co before relying on either.
Reviews: the brand’s site displays customer reviews, star ratings, and “Verified Buyer” labels, with counts on individual products ranging from the low hundreds to over 600.
Not verified here: reviewer identities, purchase status, typicality of any experience, and how the brand authenticates reviews. The review platform is not disclosed.
Not reproduced: reviews on the pages include statements about physical and emotional effects, so none are quoted.
Brand-asserted terms (not adopted here): “lab-tested,” “purest,” “premium,” “ultra-strength,” “legal alternative,” “fully legal.”
Federal-status statement: the brand’s FAQ says 7-OH is not a controlled substance under federal law. The statement is undated and does not mention the pending DEA process, the FDA’s position, or the August 26 order on related compounds.
Drug testing: the brand publishes information on the topic. No authoritative agencyment program, or laboratory tests for 7-OH. Policies vary, and this article offers no guidance on them
This section reports what the FDA and DEA have published. It is general information, not medical advice and not a statement about any particular product.
Opioid pharmacology: the FDA describes 7-OH as a mu-opioid receptor agonist. In animal studies, it produced respiratory depression at more than three times morphine’s potency, along with a reward-related response, physical dependence, and withdrawal signs.
Dependence: the FDA concludes that repeated or prolonged use would be expected to produce tolerance, physical dependence, and potentially opioid addiction. The DEA’s notice uses similar language.
Poison center data: the FDA’s report counted 53 poison-center exposure cases involving 7-OH from February through April 2025. The DEA’s notice reports 165 exposure cases from January through July 2025, with 35 percent of single-substance cases involving serious health problems and 67 percent treated at a health care facility.
Adverse events and toxicology: the DEA’s notice cites 86 FDA adverse-event reports mentioning 7-OH as of February 27, 2026, 79 of them serious and nine involving death, and 85 cases in the DEA’s toxicology program since 2019, of which 55 were fatal. Both agencies caution that interpretation is difficult, because 7-OH is also a metabolite of mitragynine and many cases involved other substances.
Combinations: the DEA’s notice calls co-ingestion with central nervous system depressants a serious concern and notes that toxicology samples often contained other drugs, including fentanyl, benzodiazepines, and ketamine.
Medication interactions: the FDA’s report cites a study finding that the body’s conversion of mitragynine to 7-OH depends heavily on the CYP3A4 enzyme, which many medications affect. That is a question for a pharmacist or physician.
Product variability: the DEA’s notice says products in this category often have ambiguous dosing and composition, with per-dose amounts ranging from about 1 mg to 700 mg in one investigation of products, and that some contain other opioid alkaloids.
Related compounds: the DEA’s August 26 order describes mitragynine pseudoindoxyl, MGM-15, and MGM-16 as potent opioid agonists and cites overdose cases in its toxicology program.
Limits of the evidence: the FDA notes the lack of clinical studies of purified 7-OH and that surveillance of 7-OH specifically only recently began.
Some researchers and policy groups argue that the evidence for singling out semi-synthetic 7-OH, or for the threshold chosen, is incomplete. Those views appear in public comments and press coverage; the agencies’ published conclusions are the ones summarized above.
Each item below was sought and not confirmed from the brand’s materials:
Whether a DEA temporary order for 7-OH (DEA-1570) has published after thehis
What the milligram figures measure on the 30mg and 60mg lines, and which strength applies to White Grape.
How the lab-reported weights and servings relate to the brand’s labeling, including the Mixed Berry alternative (1.032 g and 0.065 g against 1,200mg and 75mg) and the Watermelon report’s 0.28 g serving against the brand’s quarter-tablet serving.
What Mitraxidine is, beyond the brand’s description of a proprietary kratom-derived blend, and whether other flavors match the Mixed Berry lab report.
Whether any currently sold product contains mitragynine pseudoindoxyl, given the “Orange Citrus 7OH + Pseudo” language on one live page.
Lab reports for every flavor and strength, and why two records for Batch 14-31-058 differ on client, matrix, and weights.
Who manufactures the products. The lab reports and some third-party retailer listings associate BARS with a company called TRE House, but the Get Bars pages reviewed do not state a manufacturer, and the brand’s cGMP statement is unverified.
The terms of the 40 percent offer, including any subscription, cancellation method, and billing cycle.
Which refund window applies, 30 or 60 days.
Current law in every state, beyond Tennessee and Ohio. Florida in particular requires current primary-h official state lists
A customer-service phone number. The only number in the reviewed text appears in the privacy policy for mailing-list removal.
Search the Federal Register for “7-hydroxymitragynine” and look for a document of type “Rule,” titled “Temporary Placement,” not only a “Proposed Rule” notice of intent.
Read the DEA’s July 1, 2026 press release and check the DEA’s Diversion Control Division for updates.
Review the FDA’s 7-OH page for new warning letters, seizures, and consumer guidance.
Check your state’s legislature, health department, or board of pharmacy, because news summaries and seller lists lag behind.
Look at dates on any lab report and compare the analytes and units against the label before drawing conclusions.
Product name: Get Bars 7-OH Tablets (“BARS”)
Contracting party named in Terms: 113 Ventures, LLC
Product families: BARS 7 Hydroxy Tablets and BARS 7OH-Alternative Tablets
7-OH strengths (brand-reported): 30mg and 60mg per tablet, with conflicting pages
Alternative line (brand-reported): 300mg Mitraxidine per tablet, 75mg per serving
Servings: 4 per tablet; 16 per 4-tablet pack
Listed price (October 3, 2026): $34.99 against a crossed-out $49.99 on flavors reviewed
Offer language: “Subscribe & Save 40% Off + Free Shipping” (terms unconfirmed)
Return windows stated: 30 days and 60 days
FDA status: no FDA approval identified for the products reviewed; the FDA says 7-OH is not lawful in dietary supplements
DEA, 7-OH: notice of intent published July 6, 2026; no order located
DEA, related compounds: temporary order effective August 26, 2026
Proposed 7-OH threshold: more than 0.050 percent by weight or more than 1.00 mg per article
Support email: Info@GetBars.co
Poison Help Line: 1-800-222-1222
Get Bars 7-OH Tablets are flavored tablets sold at getbars.co in two lines: 7-OH tablets labeled 30mg or 60mg, and a separate 7OH-Alternative line the brand says contains no 7-OH. A brand-posted report for one 60mg product lists 7-OH at 21.6 percent by weight.
Is 7-OH federally scheduled right now?
As of October 3, 2026, no 7-OH temporary scheduling order was located. The DEA published a notice of intent on July 6, 2026. A notice of intent is not an order, so Schedule I status for 7-OH has not been confirmed. Three related compounds were scheduled August 26.
What is the FDA’s position on 7-OH?
The FDA describes 7-OH as a potent opioid that poses an emerging public health threat. The FDA states it is not lawful in dietary supplements or conventional foods and that no FDA-approved drug contains it. The FDA recommended Schedule I placement for concentrated 7-OH in July 2025.
